Skip to content
Screener

Pacira BioSciences, Inc. PCRX SG&A

SG&A at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$106.59M+44.8%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$1.02B+1.3%
Enterprise value$1.29B+21.7%
P/E198.5×—
P/S1.4×0.0×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Operating expenses:
Cost of goods sold (exclusive of amortization of acquired intangible assets)36,41334,306
Research and development28,07225,342
Selling, general and administrative93,94486,776
Amortization of acquired intangible assets14,32214,322
Other operating (gains) expenses, net(2,277)6,187
Total operating expenses170,474166,933
Income from operations6,9021,990

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s SG&A?
Pacira BioSciences, Inc. (PCRX) reported SG&A of $93.94M in Q1 2026.
How has Pacira BioSciences, Inc.'s SG&A changed year-over-year?
Pacira BioSciences, Inc.'s SG&A increased by 8.3% year-over-year, from $86.78M to $93.94M.
What is the long-term trend for Pacira BioSciences, Inc.'s SG&A?
Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s SG&A has grown at a 16.6% compound annual growth rate (CAGR), from $199.35M to $368.76M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Pacira BioSciences, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude